Understanding Lp(a) Levels and Their Strong Link to Heart Disease Risk

New Research Highlights Stronger Link Between Elevated Lipoprotein(a) and Major Cardiovascular Events

A growing body of evidence is sharpening the focus on lipoprotein(a), or Lp(a), as a critical but often overlooked risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent findings suggest that higher thresholds of Lp(a) are more closely associated with major cardiovascular events than previously understood, even in individuals with otherwise normal cholesterol levels. This emerging understanding is prompting calls for broader testing and targeted interventions to address what experts describe as a largely inherited and underdiagnosed contributor to heart disease.

The Threshold Matters: Higher Lp(a) Levels Correlate with Greater Risk

A study highlighted by TCTMD found that elevated Lp(a) levels—particularly those exceeding 125 nanomoles per liter (nmol/L) or 50 milligrams per deciliter (mg/dL)—are strongly linked to an increased risk of major ASCVD events, including heart attacks and strokes. The research underscores that the risk escalates with higher Lp(a) concentrations, even in individuals who maintain healthy lifestyles and have no other apparent cardiovascular risk factors.

The findings align with earlier studies, such as those published in the International Journal of Environmental Research and Public Health, which established a well-documented connection between high Lp(a) levels and both coronary and cerebrovascular disease. However, the new data refines this understanding by demonstrating that the relationship between Lp(a) and cardiovascular risk is not linear but rather threshold-dependent, with significantly heightened risk emerging at levels above the 125 nmol/L mark.

Why Healthy People Experience Heart Attacks: The Role of Lp(a)

The case of Sandra Revill Tremulis, as reported by the American Heart Association, illustrates the often-surprising role of Lp(a) in cardiovascular health. Despite maintaining a healthy lifestyle and having normal cholesterol levels, Tremulis suffered a near-fatal heart attack at age 39 due to a 95% blockage in her arteries. Subsequent testing revealed elevated Lp(a) levels, which she later learned were largely determined by her genetics. Her experience highlights a critical gap in cardiovascular risk assessment: traditional cholesterol screenings may miss this inherited risk factor, leaving individuals unaware of their vulnerability.

Experts emphasize that Lp(a) behaves differently from other cholesterol markers. Unlike low-density lipoprotein (LDL) cholesterol, which can be influenced by diet and exercise, Lp(a) levels are primarily genetically determined and remain largely unaffected by lifestyle changes. This genetic basis makes it a particularly insidious risk factor, as individuals with high Lp(a) may appear healthy by conventional measures yet face a significantly elevated risk of cardiovascular events.

Residual Cardiovascular Risk: The Hidden Danger of Lp(a)

Even among individuals who manage other cardiovascular risk factors—such as high blood pressure, diabetes, or LDL cholesterol—elevated Lp(a) can contribute to what experts term “residual risk.” This refers to the ongoing threat of cardiovascular events that persists despite optimal management of other risk factors. A study reported by News-Medical found that high Lp(a) levels are associated with this residual risk, suggesting that current preventive strategies may be insufficient for individuals with genetically elevated Lp(a).

The implications are particularly concerning for women. Research highlighted by Medscape demonstrated a strong association between high Lp(a) levels and long-term cardiovascular disease (CVD) risk in women. The study found that women with elevated Lp(a) faced a disproportionately higher risk of CVD over time, underscoring the need for gender-specific approaches to cardiovascular risk assessment and prevention.

Testing and Awareness Gaps Persist

Despite the growing recognition of Lp(a) as a major cardiovascular risk factor, testing for it remains uncommon in clinical practice. According to the Harvard Heart Letter, only 0.3% of individuals in the United States underwent Lp(a) screening between 2012 and 2019. This low testing rate is partly due to historical guidelines that did not recommend routine Lp(a) screening, as well as the lack of widely available treatments to lower Lp(a) levels.

However, the landscape is shifting. In 2024, the National Lipid Association issued its first official endorsement for one-time Lp(a) testing for all individuals. This recommendation reflects a broader consensus among international health organizations, which have long advocated for routine Lp(a) screening. The Centers for Disease Control and Prevention (CDC) also recognized high Lp(a) levels as a clinical diagnosis in 2018, further legitimizing its role as a critical risk factor.

Insurance coverage for Lp(a) testing has also improved, with most insurers now covering the test in most states. This development is expected to increase accessibility and encourage more widespread screening, particularly as new therapies for lowering Lp(a) enter the pipeline.

Emerging Treatments and Future Directions

One of the most significant barriers to addressing Lp(a)-related risk has been the lack of effective treatments. Until recently, there were no approved therapies specifically designed to lower Lp(a) levels. However, this is changing. According to the Harvard Heart Letter, five promising therapies are currently in development, offering hope for individuals with genetically elevated Lp(a). These therapies target the underlying mechanisms of Lp(a) production and could provide a much-needed tool for reducing cardiovascular risk in this population.

In the meantime, experts recommend that individuals with a family history of early-onset heart disease or unexplained cardiovascular events consider Lp(a) testing. Early identification of elevated Lp(a) levels can inform more personalized risk management strategies, such as more aggressive control of other cardiovascular risk factors or closer monitoring for early signs of disease.

The Need for Greater Awareness

Despite its significance, Lp(a) remains a relatively unknown risk factor among the general public. Sandra Revill Tremulis, who founded an organization to raise awareness about Lp(a) after her own experience, has been a vocal advocate for greater education and testing. “I just couldn’t believe that people weren’t talking about this,” she said in an interview with the American Heart Association. “I wanted to make sure that there’s help for every child who inherits this so that they can change their cardiovascular destiny.”

Her advocacy has contributed to growing recognition of Lp(a) as a public health priority. However, experts caution that awareness alone is not enough. Structural changes, such as the inclusion of Lp(a) testing in routine cardiovascular risk assessments and the development of targeted therapies, are essential to addressing this often-overlooked risk factor.

What This Means for Cardiovascular Health

The latest research on Lp(a) underscores the complexity of cardiovascular risk assessment. While traditional risk factors like high blood pressure, diabetes, and LDL cholesterol remain critical, the role of Lp(a) highlights the need for a more nuanced approach. For individuals with elevated Lp(a), even optimal management of other risk factors may not be sufficient to mitigate their cardiovascular risk fully.

As testing becomes more accessible and new treatments emerge, the hope is that individuals with high Lp(a) levels will have more tools to manage their risk. In the interim, greater awareness among both healthcare providers and the public is essential to ensuring that this inherited risk factor is no longer overlooked. For those with a family history of early heart disease or unexplained cardiovascular events, Lp(a) testing could be a critical step toward a more personalized and effective approach to heart health.

the growing body of evidence on Lp(a) serves as a reminder that cardiovascular health is influenced by a combination of genetic and lifestyle factors. By addressing both, individuals and healthcare providers can work together to reduce the burden of heart disease and improve outcomes for those at greatest risk.